Anthropic's Debut Was Ugly. Tom Lee Says That's Precisely the Point.
Anthropic (ANT) opened at $111.50 and closed at $97.17 while the S&P 500 fell 2.02% for a sixth straight session. Tom Lee calls it max pain for tech. I think he's directionally right, but this is a trade, not a thesis.
Anthropic's first day as a public company was a mess. That doesn't make it a mistake. The two things are very different, and most of the market is already confusing them.
ANT opened at $111.50 on the Nasdaq Thursday, then slid to $97.17. That's a 12.9% markdown from the first print, roughly $14 of value gone before the bell. The S&. P 500 dropped 2.02% for a sixth straight down session. All seven Magnificent Seven names closed lower. Neoclouds, the newer data center operators renting out AI compute, got sold alongside it.
Tom Lee, Fundstrat's head of research, looked at that tape and called it max pain. His read: the selloff should reward patient investors.
Here's what matters. The deal didn't fail because of Anthropic. It failed because of the calendar.
Stacking the evidence
You don't bring a marquee AI name to market into a six-day index bleed and expect a clean print. The numbers tell the story. Six consecutive red sessions in the S&. P. A 2.02% drop on debut day. Every mega-cap tech name lower. That's not a company-specific problem. That's a risk-appetite problem.
And the neocloud reaction is the piece most people will overlook. Those names don't share an underwriting syndicate with ANT. They don't share a float or a lockup. They share one thing: exposure to the AI capex trade. When they get marked down on the same day, you're watching positioning unwind, not fundamentals deteriorate.
Max pain logic is simple. When the marginal seller gets flushed out, the next move doesn't need good news. It just needs the absence of bad news.
Where the bears are right
But let's not pretend a weak debut is automatically a valuation error. Sometimes a weak debut is a weak debut.
Is $111.50 a real price or an underwriter's guess? Nobody knows yet. The first print on any IPO reflects a book that was built weeks earlier, in a different tape. And if six straight down days in the S&. P tell us anything, it's that the bid for risk is thinning at the index level, not just at the single-name level.
What the street is missing: the Magnificent Seven all closing lower on the day a major AI name lists is the actual signal. If the largest balance sheets in tech can't catch a bid into a marquee debut, the problem isn't the newcomer.
So is this a broken deal or a broken tape? That's the only question that matters, and day one can't answer it.
My verdict
Lee is directionally right. I wouldn't pound the table yet.
Here's my stance, and I'll own it: the max pain setup is real, but it's a trade, not a thesis. An IPO pop is sentiment. Sentiment reverts. Revenue doesn't. Until ANT puts a quarterly print on the tape with real inference margins and real enterprise retention, you're buying a narrative at a discount, not a business at a discount.
From a risk perspective, though, the asymmetry has shifted. Buying day-one weakness in an AI bellwether is a better bet than chasing the open. The people who got hurt Thursday were the ones paying up.
What I'm watching next: whether ANT holds $97.17 on a closing basis, whether the S&. P breaks its losing streak, and whether the neocloud names find a floor before the sector does. If those three line up, Lee looks early and correct. If they don't, max pain becomes a description of the P&. L, not a turn signal.
Conviction here should be sized small and staged. That's the honest answer.